Colorectal Cancer

Molecular characterisation of gastrointestinal tumours through genomic, transcriptomic and proteomic analysis (R. Salazar, V. Moreno).
Construction of molecular signatures for predicting colorectal cancer prognosis (R. Salazar).
Predictions of therapeutic response based on molecular tumour detection and subtype classification (R. Salazar)
New experimental therapeutic strategies to overcome resistance in colorectal cancer treatment (R. Salazar).
Research, evaluation and validation of new diagnostic biomarkers in colorectal cancer (V. Moreno).
Genetic and epigenetic determinants of susceptibility to CRC and chemotherapy toxicity (V. Moreno).
Improvement in cancer precision medication and biomarker identification using computational analysis and large-scale integration of molecular data. (X. Solé).
Stratification of CRC patients based on molecular characteristics and the level of immune-cell infiltration of their tumours (C. Santos andR. Sanz-Pamplona).
Microbiome-host interactions and colorectal cancer (V. Pimenoff, M. Obon, V. Moreno).
Prognostic and predictive values of circulating tumour DNA in metastatic colorectal cancer (C. Santos).

Fuentes P, Pelletier J, Martinez Herráez C, Diez Obrero V, Iannizzotto F, Rubio T, Garcia Cajide M, Menoyo S, Moreno V, Salazar R, Tauler A, Gentilella A. The 40S-LARP1 complex reprograms the cellular translatome upon mTOR inhibition to preserve the protein synthetic capacity. Sci Adv. 2021;7(48):doi:10.1126/sciadv.abg9275. IF:14,14.

Diez Villanueva A, Jorda M, Carreras Torres R, Alonso H, Cordero D, Guino E, Sanjuan X, Santos C, Salazar R, Sanz Pamplona R, Moreno V. Identifying causal models between genetically regulated methylation patterns and gene expression in healthy colon tissue. Clin Epigenetics. 2021;13(1):162-162. doi:10.1186/s13148-021-01148-9. IF:6,55.

Carmona Bayonas A, Jimenez Fonseca P, Valenti V, Salazar R. Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA. Ann. Oncol. 2021;32(7):938-939. doi:10.1016/j.annonc.2021.03.003. IF:32,98.

Ruffinelli,JCC,Guino,E,Cid,ND,Navarro,M,Moreno,V,Vidal,JMB,Salazar,R,Vivas,C.Early-onset colorectal cancer: 10-year cases documented in a comprehensive cancer centre illustrate the importance of a growing oncological problem.Ann. Oncol.2021.32575-575.doi:10.1016/j.annonc.2021.08.1013.

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators*(R. Salazar). Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. IF:41,32.

20MAR011. Validation of a predictive molecular signature in Neuroendocrine Tumors. (201938-30). CENTRE FOR APPLIED RESEARCH ON CANCER (ARC-NET); FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3; INSTITUTE OF CANCER RESEARCH. 2020-2023. PI: SALAZAR SOLER,RAMON

21FIS026. ¿Cómo influye el microambiente inmune en el patrón de diseminación mestatásica y supervivencia en pacientes con cáncer colorrectal? Estudio de tumores primarios y mestastásicos apareados. (PI20/00767). ISCIII. 2021-2023. PI: SANTOS VIVAS,CRISTINA.

18PSJ019. Genetic and metabolomics screening towards the precision medicine in cancer prevention. (GCTRA18022MORE). AECC; ASOCIACION INSTITUTO BIODONOSTIA; FISABIO; FUND.SANT JOAN DE DEU; FUNDACIO IDIBELL; FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA - FFIS DE LA REGION DE MURCIA; INST. D'INVESTIGACIÓ BIOMEDICA DE GIRONA DR. JOSEP TRUETA (IDIBGI); INSTITUT CATALA D'ONCOLOGIA; INSTITUTO DE SALUD PUBLICA Y LABORAL DE NAVARRA; ISCIII; ISGLOBAL; UNIVERSIDAD DE CANTABRIA; UNIVERSIDAD DE GRANADA; UNIVERSIDAD DE HUELVA; UNIVERSIDAD DE LEON; UNIVERSIDAD DE OVIEDO. 2018-2024. PI: MORENO AGUADO,VICTOR.

20FIS019. Refining the consensus molecular subtypes classification: prognostic and therapeutic implications in stage II colon cancer. (PI19/01903). ISCIII. 2020-2022. PI: SALAZAR SOLER,RAMON.

18FIS005. Estudio de las interacciones microbioma-anfitrión para la prevención del cáncer colorrectal (Colonbiome). (PI17/00092). ISCIII. 2018-2022. PI: MORENO AGUADO,VICTOR.

METODO PARA DETERMINAR EL RIESGO DE DESARROLLAR METASTASIS CEREBRAL Y UN KIT PARA LLEVAR A CABO DICHO PROCEDIMIENTO

SANZ PAMPLONA REBECA (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ ANGELS (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL BALDOMERO (Inventores-as/autores-as/obtentores-as); MORENO AGUADO VICTOR RAUL (Inventores-as/autores-as/obtentores-as); GIL GIL JUAN MIGUEL (Inventores-as/autores-as/obtentores-as)

METHOD FOR DETERMINING THE RISK OF DEVELOPING BRAIN METASTASIS, AND A KIT TO CARRY OUT SAID METHOD

Sanz Pamplona, Rebeca (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ, Angels (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL, Baldomero (Inventores-as/autores-as/obtentores-as); Moreno Aguado, Victor Raul (Inventores-as/autores-as/obtentores-as); Gil Gil, Juan Miguel (Inventores-as/autores-as/obtentores-as)

See full list

Participation in international consortiums: MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer) and FIGI (Using functional genomics to inform gene environment interactions for CRC).
Colonomics as a platform for biomarker discovery and characterisation of CRC.
Clinical validation of ColoPrint®, a phase II prognostic genetic signature and new consensus on molecular subtype classification (CMS 1-4)